Transition Therapeutics to license to Eli Lilly
Biopharmaceutical company Transition Therapeutics Inc. (Nasdaq: TTHI) said it will license exclusive worldwide rights to pharmaceutical products juggernaut Eli Lilly and Co. (NYSE: LLY) to develop and commercialize Transition's gastrin based therapies. Shares climbed 14.3%, or $1.59, to $12.70 in pre-market trading.
For detailed price information and recent news stories about Transition Therapeutics, click TTHI.
